Trials / Completed
CompletedNCT02542267
In-Stent Restenosis Post-Approval Study
Post-Approval Study of the GORE® VIABAHN® Endoprosthesis for the Treatment of In-Stent Restenosis (ISR) in the Superficial Femoral Artery (SFA)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 108 (actual)
- Sponsor
- W.L.Gore & Associates · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the ISR 14-04 study is to evaluate post-market safety and effectiveness of GORE® VIABAHN® Endoprosthesis for treatment of In-Stent Restenosis of the Superficial Femoral Artery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Gore VIABAHN Endoprosthesis |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2019-07-01
- Completion
- 2021-07-01
- First posted
- 2015-09-04
- Last updated
- 2023-10-16
- Results posted
- 2020-08-21
Locations
23 sites across 4 countries: United States, Germany, Italy, Sweden
Source: ClinicalTrials.gov record NCT02542267. Inclusion in this directory is not an endorsement.